News | January 25, 2010

Clinical Data Shows Benefit of Endothelial Cell Capture Stent

January 25, 2010 – Trials for a stent that attracts endothelial progenitor cells show positive results in patients with bifurcation lesions and those with non-ST-segment elevation acute coronary syndrome.

OrbusNeich announced the clinical data at Asia PCR/Singapore LIVE 2010, demonstrating the benefits of the Genous Bio-Engineered R Stent in the treatment of two challenging patient subsets. The stent uses endothelial progenitor cell (EPC) capture technology to promote rapid healing of the vessel and to prevent neointimal hyperplasia.

Professor Robbert de Winter, M.D., Ph.D., of the Academic Medical Center (AMC) in Amsterdam, presented "One Year Clinical Outcome after Provisional T Stenting with the Endothelial Progenitor Cell Capturing Stent for Bifurcation Lesions." The information featured a single-center study with 178 patients that compared the Genous Bio-Engineered R Stent to a previous bare metal stent control group of 465 patients at the AMC. A 32 percent reduction of the composite of cardiac death, myocardial infarction or target lesion revascularization was reported between these two groups. The cumulative rate of definite or probable stent thrombosis was reduced by 57 percent in the Genous stent-treated group compared to the control group.

"Bifurcation lesions remain a challenge for interventional cardiologists," said Dr. de Winter said. "The Genous Bio-Engineered R Stent, with a low rate of stent thrombosis, is an alternative for this challenging patient group."

Wojciech Wojakowski, M.D., from Medical University of Silesia, Poland, presented data on the JACK-EPC trial. The trial compared the efficiency of high-dose atorvastatin and endothelial progenitor-capture stents versus bare metal stents, in the reduction of neointimal formation in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). The randomized study with 60 patients compared the Genous with bare metal stents with concomitant high-dose atorvastatin in the reduction of neointimal hyperplasia assessed by coronary angiography and IVUS after six months.

In the JACK-EPC trial, the Genous stent induced less neointimal hyperplasia and a lower binary restenosis rate of 13 percent, compared to 26.6 percent in the control group. The major adverse cardiac events (MACE) rate was reported at only 10 percent in the Genous treated patient group versus 16 percent in the bare metal stent treated group.

"In our small study, we observed a lower amount of neointimal proliferation with the EPC capture stent compared to the bare metal stent control," said Dr. Wojakowski. "Good safety is indicated by comparable stent thrombosis. We think this makes the Genous stent a very promising treatment strategy for ACS patients, especially those with high risk of bleeding or not eligible for prolonged dual antiplatelet therapy due to allergy to ASA or clopidogrel."

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init